Cas13a/C2c2 - A Dual Function Programmable RNA Endoribonuclease

Tech ID: 25839 / UC Case 2016-163-0

Patent Status

Country Type Number Dated Case
Japan Issued Patent 7437474 02/14/2024 2016-163
United States Of America Issued Patent 11,840,725 12/12/2023 2016-163
United States Of America Issued Patent 11,827,919 11/28/2023 2016-163
China Issued Patent ZL201780048641.6 01/03/2023 2016-163
Australia Issued Patent 2017283538 11/03/2022 2016-163
United States Of America Issued Patent 11,459,599 10/04/2022 2016-163
United States Of America Issued Patent 11,459,600 10/04/2022 2016-163
Hong Kong Issued Patent 40007733 09/16/2022 2016-163
Belgium Issued Patent 3471749 01/12/2022 2016-163
Switzerland Issued Patent 3471749 01/12/2022 2016-163
Germany Issued Patent 602017052315.1 01/12/2022 2016-163
Denmark Issued Patent 3471749 01/12/2022 2016-163
European Patent Office Issued Patent 3471749 01/12/2022 2016-163
Spain Issued Patent 3471749 01/12/2022 2016-163
Finland Issued Patent 3471749 01/12/2022 2016-163
France Issued Patent 3471749 01/12/2022 2016-163
United Kingdom Issued Patent 3471749 01/12/2022 2016-163
Ireland Issued Patent 3471749 01/12/2022 2016-163
Iceland Issued Patent 3471749 01/12/2022 2016-163
Italy Issued Patent 3471749 01/12/2022 2016-163
Liechtenstein Issued Patent 3471749 01/12/2022 2016-163
Luxembourg Issued Patent 3471749 01/12/2022 2016-163
Netherlands (Holland) Issued Patent 3471749 01/12/2022 2016-163
Norway Issued Patent 3471749 01/12/2022 2016-163
Sweden Issued Patent 3471749 01/12/2022 2016-163
United States Of America Issued Patent 10,494,664 12/03/2019 2016-163
United States Of America Issued Patent 10,337,051 07/02/2019 2016-163
United Kingdom Issued Patent 2557153 03/20/2019 2016-163
Germany Issued Patent 212017000061.9 12/04/2018 2016-163
Germany Issued Patent 212017000062.7 11/29/2018 2016-163
Germany Issued Patent 212017000056.2 11/21/2018 2016-163
European Patent Office Published Application 4036249 A1 08/03/2022 2016-163
Canada Published Application WO 2017/218573 12/21/2017 2016-163
 

Additional Patent Pending

Brief Description


Bacterial adaptive immune systems employ CRISPRs and CRISPR-associated (Cas) proteins for RNA-guided nucleic acid cleavage. Although generally targeted to DNA substrates, the Type VI CRISPR system directs interference complexes against single-stranded RNA substrates and in Type VI CRISPR systems, the single-subunit Cas13a/C2c2 protein functions as an RNA-guided RNA endonuclease.

 

UC Berkeley researchers have discovered that the CRISPR-Cas13a/C2c2 has two distinct RNase activities that enable both single stranded target RNA detection and multiplexed guide-RNA processing.  These dual RNase functions were found to be chemically and mechanistically different from each other and from the CRISPR RNA processing behavior of the evolutionarily unrelated CRISPR enzyme Cpf1.  Methods for detecting the single stranded target RNA were also discovered using a Cas13a/C2c2 guide RNA and a Cas13a/C2c2 protein in a sample have a plurality of RNAs as well as methods of cleaving a precursor Cas13a/C2c2 guide RNA into two or more Cas13a/C2c2 guide RNAs.

 

Suggested uses


 

  • Multiplexed guide-RNA processing
  • Diagnostic for sensitive target RNA detection

 

Advantages

 

  • Detects target RNA directly without considerable engineering or stringent design constraints for each new RNA target
  • Cleavage potent and detectable at extremely low levels of activated protein
  • Highly specific method of detection
  • Conventional detection methods can be used (e.g., using a labeled detector RNA)

 

Publication

Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Doudna, Jennifer A.

Other Information

Keywords

Cas13a,CRISPR, genome editing, RNA, C2c2

Categorized As

Additional Technologies by these Inventors